Michael has made over 2 trades of the Sutro Biopharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Michael bought 500,000 units of STRO stock worth $5,000,000 on 20 November 2017.
The largest trade Michael's ever made was buying 500,000 units of Sutro Biopharma Inc stock on 20 November 2017 worth over $5,000,000. On average, Michael trades about 33,450 units every 36 days since 2015. As of 20 November 2017 Michael still owns at least 1,868,961 units of Sutro Biopharma Inc stock.
You can see the complete history of Michael Ross stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 500 Totten Pond Road, 6th Floor, Waltham, MA 02451, United States.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund y Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: